key: cord-0731990-6klrjk07 authors: Karippacheril, John George; Jain, Amit title: Clot-in-transit cardiopulmonary thrombosis during convalescent phase of COVID-19 date: 2021-07-05 journal: Korean J Anesthesiol DOI: 10.4097/kja.21199 sha: a026a3c004c49334380a462fd2aa0198db2b51f3 doc_id: 731990 cord_uid: 6klrjk07 nan The Korean Society of Anesthesiologists, 2022 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons. org/licenses/by-nc/4.0/), which permits unrestricthed non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 3 days. Follow-up echocardiography a week later showed no residual thrombus and normal right ventricular function. While thromboembolic complications occur with an incidence as high as 20% to 30% in patients with severe COVID-19 [1] , only a few reports have described such complications following recovery from mild COVID-19 [1, 2] . A single-center report of 163 patients without post-discharge thromboprophylaxis suggested a 2.5% cumulative incidence of thrombosis at 30 days following discharge, including segmental pulmonary embolism, intracardiac thrombus, thrombosed arteriovenous fistula, and ischemic stroke [4] . Tu et al. [5] recently reported 10 cases of acute ischemic stroke in adults aged ≤ 50 years in the convalescent phase of asymptomatic COVID-19. The median (Q1, Q3) time from a positive serological test result to acute ischemic stroke was 54.5 (0, 130) days. However, none of these patients had received thromboprophylaxis. Thus, the present case is unique, as the patient developed massive acute pulmonary embolism nearly 42 days post-asymptomatic COVID-19 despite thromboprophylaxis. Further, this case highlights the possibility of prolonged COVID-19-associated coagulopathy (CAC) following asymptomatic SARS-CoV-2 infection resulting in massive cardiopulmonary thrombosis in the convalescent phase. Pow et al. [2] reported a similar case of submassive pulmonary embolism during the convalescent phase in a patient with minimally symptomatic SARS-CoV-2 infection. However, as their patient had a positive nasal swab result on readmission, it raised the possibility of reinfection resulting in a hypercoagulable state instead of prolonged CAC as a cause of submassive pulmonary embolism. Probable mechanisms B D A C of CAC and thrombosis in post-acute COVID-19 syndrome include dysregulated renin-angiotensin system activity, endothelial dysfunction, cytokine-induced inflammation, complement and platelet activation, platelet-leukocyte interaction, neutrophilic extracellular traps, lupus anticoagulant, and up-regulation of tissue factor, thrombin, and fibrin with down-regulation of fibrinolytic and anticoagulant mechanisms [1, 2, 4] . The risk of thrombotic complications in the post-acute COVID-19 phase is probably linked to the duration and severity of a hyperinflammatory state, although how long this persists is unknown [4] . Given the increase in thrombotic complications in post-acute COVID-19, Nalbandian et al. [4] argued that extended post-hospital follow-up (up to 6 weeks) and prolonged primary thromboprophylaxis (up to 45 days) in those managed as outpatients may have a more favorable risk-benefit ratio. However, individual patient-level considerations for risk versus benefit should dictate recommendations at this time. Elevated D-dimer levels, in addition to comorbidities such as cancer and immobility, may help to stratify patients at the highest risk of post-acute thrombosis [4] . Notably, increased D-dimer levels ( > 500 ng/ml) were observed in 25.3% of patients up to 4 months post-SARS-CoV-2 infection [3] . Thus, elevated D-dimer levels and history of deep vein thrombosis (even though not associated with hypercoagulable disorders) might have placed our patient at high risk of thrombotic complications despite thromboprophylaxis and ambulation. Furthermore, as optimal therapy is not defined for COVID-19-associated thrombosis, thrombolytic therapy might have resulted in an unfavorable outcome in our patient. In conclusion, we highlight the possibility of late-onset acute COVID-19-associated thrombosis even in asymptomatic infections, the lack of an established dose and duration of thromboprophylaxis, and the risk of failure of thrombolytic therapy. Close patient follow-up is warranted in the convalescent phase of COVID-19. None. No potential conflict of interest relevant to this article was reported. Late acute pulmonary embolism after mild Coronavirus Disease 2019 (COVID-19): a case series Acute submassive pulmonary embolism after SARS-CoV-2 infection: a case report of reinfection or prolonged hypercoagulable state Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response Post-acute COVID-19 syndrome Acute ischemic stroke during the convalescent phase of asymptomatic COVID-2019 infection in men John George Karippacheril (Conceptualization; Data curation; Formal analysis; Investigation; Resources; Writing -original draft; Writing -review & editing) Amit Jain (Conceptualization; Writing -review & editing) ORCID John George Karippacheril, https://orcid.org/0000-0003-1737-9371 Amit Jain, https://orcid.org/0000-0002-0012-9491